| Year |
Citation |
Score |
| 2023 |
Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, Ruhaak LR, Schwertfeger M, Tsimikas S, White HD, Steg PG, et al. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests. Circulation. PMID 37632469 DOI: 10.1161/CIRCULATIONAHA.123.066398 |
0.323 |
|
| 2023 |
Suc G, Schwartz GG, Goodman SG, Jukema JW, Manvelian G, Poulouin Y, Pordy R, Scemama M, Szarek M, Steg PG. Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes. Bmc Ophthalmology. 23: 301. PMID 37415129 DOI: 10.1186/s12886-023-03065-2 |
0.307 |
|
| 2023 |
Suc G, Schwartz GG, Goodman SG, Jukema JW, Manvelian G, Poulouin Y, Pordy R, Scemama M, Szarek M, Steg PG. Effect of alirocumab on cataracts in patients with acute coronary syndromes. Bmc Ophthalmology. 23: 279. PMID 37328736 DOI: 10.1186/s12886-023-03012-1 |
0.337 |
|
| 2023 |
Steg PG, Szarek M, Valgimigli M, Islam S, Zeiher AM, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Gotcheva N, Harrington RA, Jukema JW, Kim HS, Kim SH, et al. Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome. The Canadian Journal of Cardiology. PMID 37116789 DOI: 10.1016/j.cjca.2023.04.018 |
0.402 |
|
| 2023 |
Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, Fazio S, Fras Z, Goodman SG, Harrington RA, Jukema JW, Manvelian G, Pordy R, Ray KK, Scemama M, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. European Heart Journal. PMID 36879424 DOI: 10.1093/eurheartj/ehad144 |
0.369 |
|
| 2022 |
Moriarty PM, Steg PG, McGinniss J, Zeiher AM, White HD, Manvelian G, Pordy R, Loy M, Jukema JW, Harrington RA, Gray JV, Gorby LK, Goodman SG, Diaz R, Bittner VA, ... ... Szarek M, et al. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. Journal of Clinical Lipidology. PMID 36153281 DOI: 10.1016/j.jacl.2022.08.004 |
0.345 |
|
| 2022 |
Toth PP, Schwartz GG, Nicholls SJ, Khan A, Szarek M, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Lebioda K, Wong NCW, Sweeney M, Ray KK. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease. American Journal of Preventive Cardiology. 11: 100372. PMID 36039183 DOI: 10.1016/j.ajpc.2022.100372 |
0.334 |
|
| 2022 |
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, et al. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 101161CIRCULATIONAHA. PMID 35770629 DOI: 10.1161/CIRCULATIONAHA.121.057807 |
0.323 |
|
| 2022 |
Landmesser U, McGinniss J, Steg PG, Bhatt DL, Bittner VA, Diaz R, Dilic M, Goodman SG, Jukema JW, Loy M, Pećin I, Pordy R, Poulsen SH, Szarek M, White HD, et al. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. European Journal of Preventive Cardiology. PMID 35708715 DOI: 10.1093/eurjpc/zwac107 |
0.365 |
|
| 2022 |
Chiang CE, Schwartz GG, Elbez Y, Szarek M, Bhatt DL, Bittner VA, Diaz R, Erglis A, Goodman SG, Hagström E, Jukema JW, Liberopoulos E, Loy M, Pordy R, White HD, et al. Alirocumab and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: Prespecified Sub-analysis from ODYSSEY OUTCOMES. The Canadian Journal of Cardiology. PMID 35644332 DOI: 10.1016/j.cjca.2022.05.021 |
0.361 |
|
| 2022 |
Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. Journal of the American Heart Association. e025504. PMID 35621222 DOI: 10.1161/JAHA.122.025504 |
0.349 |
|
| 2022 |
Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, et al. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet. Diabetes & Endocrinology. 10: 330-340. PMID 35378068 DOI: 10.1016/S2213-8587(22)00043-2 |
0.333 |
|
| 2021 |
Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, Capell WH, Hsia J, Beckman JA, Brodmann M, Diaz R, Habertheuer P, Leeper NJ, Powell RJ, Sillesen H, et al. Reduction in Acute Limb Ischemia with Rivaroxaban versus Placebo in Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD. Circulation. PMID 34637332 DOI: 10.1161/CIRCULATIONAHA.121.055146 |
0.319 |
|
| 2021 |
Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, et al. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. European Journal of Preventive Cardiology. PMID 34463737 DOI: 10.1093/eurjpc/zwab128 |
0.306 |
|
| 2021 |
Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR, Hess CN, Capell WH, Bracken T, Szarek M, Mátyás L, Krievins DK, Nault P, Stefanov S, Haskell LP, et al. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. European Heart Journal. PMID 34430972 DOI: 10.1093/eurheartj/ehab408 |
0.304 |
|
| 2021 |
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology. 78: 421-433. PMID 34325831 DOI: 10.1016/j.jacc.2021.04.102 |
0.334 |
|
| 2021 |
Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, et al. Total Ischemic Event Reduction with Rivaroxaban after Peripheral Arterial Revascularization in the VOYAGER PAD Trial. Journal of the American College of Cardiology. PMID 34010631 DOI: 10.1016/j.jacc.2021.05.003 |
0.316 |
|
| 2021 |
Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner Ž, Roe MT, Szarek M, Tse HF, White HD, et al. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology. 28: 33-43. PMID 33755145 DOI: 10.1177/2047487320941987 |
0.396 |
|
| 2021 |
Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M. Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation. PMID 33438437 DOI: 10.1161/CIRCULATIONAHA.120.049447 |
0.415 |
|
| 2021 |
Ostadal P, Steg PG, Poulouin Y, Bhatt D, Bittner V, Chua T, Diaz R, Goodman S, Harrington R, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, et al. METABOLIC RISK FACTORS AND THE EFFECT OF ALIROCUMAB ON CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROME: AN ANALYSIS OF THE ODYSSEY OUTCOMES RANDOMIZED CONTROLLED TRIAL Journal of the American College of Cardiology. 77: 150. DOI: 10.1016/S0735-1097(21)01509-6 |
0.374 |
|
| 2020 |
Schwartz GG, Szarek M, Bittner VA, Steg PG. Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial". Circulation. 142: e335-e336. PMID 33196306 DOI: 10.1161/CIRCULATIONAHA.120.050609 |
0.303 |
|
| 2020 |
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal. PMID 33051646 DOI: 10.1093/eurheartj/ehaa649 |
0.387 |
|
| 2020 |
Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal. PMID 32820320 DOI: 10.1093/Eurheartj/Ehaa498 |
0.424 |
|
| 2020 |
Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner Ž, Roe MT, Szarek M, Tse HF, White HD, et al. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology. 2047487320941987. PMID 32718237 DOI: 10.1177/2047487320941987 |
0.486 |
|
| 2020 |
Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K, Joulain F, Jukema JW, Li QH, Mahaffey KW, Sanchez RJ, et al. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology. 75: 2297-2308. PMID 32381160 DOI: 10.1016/J.Jacc.2020.03.029 |
0.474 |
|
| 2020 |
Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of a Randomized Clinical Trial. Circulation. PMID 32223446 DOI: 10.1161/Circulationaha.120.046524 |
0.492 |
|
| 2020 |
Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimský P, Avezum A, Diaz R, et al. The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. Circulation. PMID 32223318 DOI: 10.1161/Circulationaha.120.046448 |
0.407 |
|
| 2020 |
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories in the SPARCL Trial. Journal of the American College of Cardiology. PMID 32194196 DOI: 10.1016/J.Jacc.2020.03.015 |
0.38 |
|
| 2020 |
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Schwartz GG. Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. Journal of the American College of Cardiology. 75: 448-451. PMID 32000957 DOI: 10.1016/J.Jacc.2019.11.030 |
0.493 |
|
| 2020 |
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American College of Cardiology. 75: 133-144. PMID 31948641 DOI: 10.1016/J.Jacc.2019.10.057 |
0.452 |
|
| 2020 |
Zahger D, Szarek M, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Jukema JWW, Kiss RG, McGinniss J, Harrington RA, Moriarty PM, Pordy R, Reiner Z, Loy M, et al. Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial Circulation. 142. DOI: 10.1161/CIRC.142.SUPPL_3.15281 |
0.42 |
|
| 2020 |
Mita M, Mita A, Hamilton E, Falchook GS, Postow M, Chmielowski B, Schilder RJ, Strauss J, Lim E, Pant S, Jain A, Rixe O, Redman R, Kim KB, Dragovich T, ... ... Szarek M, et al. Abstract LB-133: Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-133 |
0.349 |
|
| 2020 |
Lim E, Hamilton EP, Redman R, Postow MA, Schilder RJ, Mita MM, Mita AC, Chmielowski B, Strauss J, Jain A, Pant S, Rixe O, Dragovich T, Harvey RD, Puzanov I, ... ... Szarek M, et al. Abstract CT146: RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): Initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct146 |
0.369 |
|
| 2020 |
Schwartz G, Szarek M, Bhatt D, Bittner V, Diaz R, Goodman S, Harrington R, Jukema J, Kim Y, Li Q, Manvelian G, White H, Zeiher A, Steg P. Low-density lipoprotein cholesterol <50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-matched analysis of the ODYSSEY OUTCOMES trial European Heart Journal. 41. DOI: 10.1093/ehjci/ehaa946.1736 |
0.381 |
|
| 2020 |
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein L, Laskey R, Sillesen H, Welch KM. Atorvastatin Reduces Total Events Overall And Across Vascular Beds In The Sparcl Trial Journal of the American College of Cardiology. 75: 2202. DOI: 10.1016/S0735-1097(20)32829-1 |
0.391 |
|
| 2020 |
Landmesser U, McGinniss J, Steg PG, Bhatt D, Bittner V, Diaz R, Goodman S, Harrington RA, Jukema JW, Laucevicius A, Pecin I, Pordy R, Poulsen S, Roe M, Sourdille T, ... Szarek M, et al. Achievement Of New European Dyslipidemia-Guideline Low-Density Lipoprotein Cholesterol Treatment Goals After Acute Coronary Syndrome: Insights From Odyssey Outcomes Journal of the American College of Cardiology. 75: 1978. DOI: 10.1016/S0735-1097(20)32605-X |
0.363 |
|
| 2020 |
Hagstrom E, Steg PG, Szarek M, Bhatt D, Bittner V, Danchin N, Diaz R, Goodman S, Harrington RA, Jukema JW, Kim Y, Liberopoulos E, Marx N, McGinniss J, Roe M, et al. Apolipoprotein B, Pcsk9 Inhibition With Alirocumab, And Ischemic Cardiovascular Events After Acute Coronary Syndrome: Insights From The Odyssey Outcomes Trial Journal of the American College of Cardiology. 75: 75. DOI: 10.1016/S0735-1097(20)30702-6 |
0.341 |
|
| 2019 |
Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang CE, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim YU, Pordy R, Roe MT, ... ... Szarek M, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal. PMID 31732742 DOI: 10.1093/Eurheartj/Ehz809 |
0.467 |
|
| 2019 |
Damask A, Steg PG, Schwartz GG, Szarek M, Hagström E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, Banerjee P, Manvelian G, Pordy R, Hess S, Overton JD, et al. Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial. Circulation. PMID 31707832 DOI: 10.1161/Circulationaha.119.044434 |
0.479 |
|
| 2019 |
Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, et al. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation. Cardiovascular Quality and Outcomes. 12: e005858. PMID 31707826 DOI: 10.1161/Circoutcomes.119.005858 |
0.437 |
|
| 2019 |
Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner Z, Roe MT, Tse HF, Valdovinos PCM, White HD, Zeiher AM, ... Szarek M, et al. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation. PMID 31707788 DOI: 10.1161/Circulationaha.119.043826 |
0.364 |
|
| 2019 |
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, et al. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. PMID 31475572 DOI: 10.1161/Circulationaha.119.042551 |
0.435 |
|
| 2019 |
Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Harrington RA, Jukema JW, Kedev S, Letierce A, Moryusef A, Pordy R, et al. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology. 74: 1177-1186. PMID 31466614 DOI: 10.1016/J.Jacc.2019.07.015 |
0.419 |
|
| 2019 |
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet. Diabetes & Endocrinology. PMID 31272931 DOI: 10.1016/S2213-8587(19)30158-5 |
0.397 |
|
| 2019 |
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal. PMID 31121022 DOI: 10.1093/Eurheartj/Ehz299 |
0.427 |
|
| 2019 |
Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, et al. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation. PMID 31117810 DOI: 10.1161/Circulationaha.118.038840 |
0.455 |
|
| 2019 |
Schwartz GG, Steg PG, Szarek M. Alirocumab after Acute Coronary Syndrome. Reply. The New England Journal of Medicine. 380: 2077. PMID 31116934 DOI: 10.1056/Nejmc1902955 |
0.382 |
|
| 2019 |
Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, et al. Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology. PMID 30898609 DOI: 10.1016/J.Jacc.2019.03.013 |
0.506 |
|
| 2019 |
Schwartz G, Szarek M, Li QH, Chiang CE, Diaz R, Hagstrom E, Huo Y, Jukema JW, Lecorps G, Moryusef A, Pordy R, White HD, Yusoff K, Zeiher AM, Steg PG. P1226Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES European Heart Journal. 40. DOI: 10.1093/Eurheartj/Ehz748.0184 |
0.435 |
|
| 2019 |
Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Parkhomenko A, Pordy R, Reiner Z, Szarek M, Tse HF, Zeiher AM, Schwartz GG, Steg PG. 4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment European Heart Journal. 40. DOI: 10.1093/Eurheartj/Ehz745.0119 |
0.449 |
|
| 2019 |
Roe MT, Szarek M, Li QH, Bhatt DL, Bittner V, Goodman SG, Harrington RA, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Vogel RA, Baccara-Dinet MT, Steg PG, Schwartz GG. 4114Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy European Heart Journal. 40. DOI: 10.1093/Eurheartj/Ehz745.0118 |
0.425 |
|
| 2019 |
Jukema JW, Szarek M, Roe M, Bhatt DL, Bittner V, Silva HAd, Diaz R, Goodman S, Hanotin C, Edelberg J, Harrington R, Karpov Y, Moryusef A, Pordy R, Prieto J, et al. Post-Acute Coronary Syndrome Patients With Polyvascular Disease Derive Large Absolute Benefit From Alirocumab: Odyssey Outcomes Journal of the American College of Cardiology. 73: 2034. DOI: 10.1016/S0735-1097(19)32640-3 |
0.467 |
|
| 2019 |
Goodman SG, Aylward P, Szarek M, Chumburidze V, Bhatt DL, Bittner V, Diaz R, Edelberg J, Hanotin C, Harrington RA, Jukema JW, Kedev S, Moryusef A, Pordy R, López GAR, et al. Patients With Acute Coronary Syndrome, Elevated Atherogenic Lipoproteins, And Prior Coronary Artery Bypass Grafting Derive Large Absolute Benefit From Alirocumab: Insights From The Odyssey Outcomes Trial Journal of the American College of Cardiology. 73: 30. DOI: 10.1016/S0735-1097(19)30639-4 |
0.399 |
|
| 2018 |
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology. PMID 30428396 DOI: 10.1016/j.jacc.2018.10.039 |
0.48 |
|
| 2018 |
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine. PMID 30403574 DOI: 10.1056/NEJMoa1801174 |
0.383 |
|
| 2018 |
Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29597002 DOI: 10.1016/J.Bbmt.2018.03.019 |
0.331 |
|
| 2018 |
Mita M, Mita A, Chmielowski B, Postow M, Hamilton E, Pant S, Waltzman R, Rowinsky E, Szarek M, Gonsalves F, Kurth I, Andreu C, Pollack I, Mucida D, Tanqueco R, et al. Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B001 |
0.328 |
|
| 2018 |
White H, Steg P, Szarek M, Bhatt D, Bittner V, Diaz R, Edelberg J, Goodman S, Hantoin C, Harrington R, Jukema J, Lecorps G, Moryusef A, Pordy R, Roe M, et al. Cardiovascular Outcomes With Alirocumab After Acute Coronary Syndrome: Results of the Odyssey Outcomes Trial Heart Lung and Circulation. 27. DOI: 10.1016/J.Hlc.2018.06.585 |
0.311 |
|
| 2018 |
Bittner V, Szarek M, Aylward PE, Bhatt DL, Diaz R, Fras Z, Goodman S, Hanotin C, Harrington R, Jukema JW, Loizeau V, Moriarty P, Moryusef A, Pordy R, Roe MT, et al. Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial Atherosclerosis Supplements. 32: 24-25. DOI: 10.1016/J.Atherosclerosissup.2018.04.072 |
0.309 |
|
| 2017 |
Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. European Journal of Preventive Cardiology. 2047487317708677. PMID 28504565 DOI: 10.1177/2047487317708677 |
0.502 |
|
| 2017 |
Goodman SG, Schwartz G, Bhatt DL, Bittner V, Diaz R, Hanotin C, Harrington R, Jukema J, Moryusef A, Pordy R, Roe M, Sasiela WJ, Szarek M, Tamby J, White H, et al. Use Of High-Intensity Statin Therapy Post-Acute Coronary Syndrome In The Ongoing Odyssey Outcomes Trial Of Alirocumab, A Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data Journal of the American College of Cardiology. 69: 153. DOI: 10.1016/S0735-1097(17)33542-8 |
0.495 |
|
| 2017 |
White H, Goodman S, Schwartz G, Bhatt D, Bittner V, Diaz R, Hanotin C, Harrington R, Jukema J, Moryusef A, Pordy R, Roe M, Sasiela W, Szarek M, Tamby J, et al. Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, A Proprotein Convertase Subtilisin/Kexin type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data Heart Lung and Circulation. 26. DOI: 10.1016/J.Hlc.2017.06.604 |
0.325 |
|
| 2015 |
Balucani C, Bianchi R, Ramkishun C, Weedon J, Law S, Szarek M, Rojas-Soto D, Tariq S, Levine SR. Rapidly improving stroke symptoms: a pilot, prospective study. Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association. 24: 1211-6. PMID 25869774 DOI: 10.1016/J.Jstrokecerebrovasdis.2015.01.017 |
0.331 |
|
| 2014 |
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, ... ... Szarek M, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. American Heart Journal. 168: 682-9. PMID 25440796 DOI: 10.1016/J.Ahj.2014.07.028 |
0.52 |
|
| 2014 |
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 124: 385-92. PMID 24859366 DOI: 10.1182/Blood-2014-04-566737 |
0.347 |
|
| 2014 |
Fehniger TA, Stuart RK, Cooley SA, Miller JS, Curtsinger J, Hillman TM, Silver N, Szarek M, Lowdell MW, Gorelik L, Rowinsky E. Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission Blood. 124: 2320-2320. DOI: 10.1182/Blood.V124.21.2320.2320 |
0.326 |
|
| 2013 |
Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Ravandi F, Kadia TM, Andreeff M, Cortes JE, Hoberman K, ... Szarek M, et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. Journal of Clinical Oncology. 31: 7029-7029. DOI: 10.1200/Jco.2013.31.15_Suppl.7029 |
0.355 |
|
| 2013 |
Frankel AE, Woo JH, Mauldin JP, Carraway HE, Frankfurt O, Forman SJ, Vasu S, Pemmaraju N, Konopleva M, Hogge DE, Garanache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Bergstein I, et al. An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Blood. 122: 2682-2682. DOI: 10.1182/Blood.V122.21.2682.2682 |
0.345 |
|
| 2012 |
Callahan AS, Szarek M, Patton JW, Sillesen AS, Jones A, Churchwell K, Holliday HD. Maximum carotid artery wall thickness and risk factors in a young primary prevention population. Brain and Behavior. 2: 590-4. PMID 23139904 DOI: 10.1002/Brb3.82 |
0.32 |
|
| 2012 |
Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Kadia TM, Ravandi F, Andreeff M, Cortes JE, Hoberman K, Szarek M, Rowinsky E, et al. SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML Blood. 120: 3625-3625. DOI: 10.1182/Blood.V120.21.3625.3625 |
0.371 |
|
| 2010 |
Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Lindahl C, Szarek M. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). The American Journal of Cardiology. 106: 354-9. PMID 20643245 DOI: 10.1016/J.Amjcard.2010.03.033 |
0.445 |
|
| 2009 |
Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. Journal of the American College of Cardiology. 54: 2353-7. PMID 20082922 DOI: 10.1016/J.Jacc.2009.08.035 |
0.395 |
|
| 2009 |
Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. Journal of the American College of Cardiology. 53: 2186-96. PMID 19497447 DOI: 10.1016/J.Jacc.2009.02.041 |
0.422 |
|
| 2009 |
Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups On Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 16: 315-20. PMID 19322096 DOI: 10.1097/Hjr.0B013E32832130F5 |
0.48 |
|
| 2009 |
Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). The American Journal of Cardiology. 103: 577-82. PMID 19231315 DOI: 10.1016/J.Amjcard.2008.10.029 |
0.381 |
|
| 2009 |
Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clinical Chemistry. 55: 473-80. PMID 19147732 DOI: 10.1373/Clinchem.2008.111401 |
0.341 |
|
| 2009 |
Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HAW, Newman CB, Szarek M, DeMicco DA, Durrington PN. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS) Diabetologia. 52: 218-225. PMID 18972097 DOI: 10.1007/S00125-008-1176-8 |
0.386 |
|
| 2009 |
Frydman H, Szarek M. Nonparametric estimation in a Markov "illness-death" process from interval censored observations with missing intermediate transition status. Biometrics. 65: 143-51. PMID 18505421 DOI: 10.1111/J.1541-0420.2008.01056.X |
0.308 |
|
| 2008 |
Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Demicco DA, Auster S, Fuller JH. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes & Vascular Disease Research. 5: 177-83. PMID 18777490 DOI: 10.3132/Dvdr.2008.029 |
0.434 |
|
| 2008 |
Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 117: 3002-9. PMID 18519851 DOI: 10.1161/Circulationaha.107.713438 |
0.422 |
|
| 2008 |
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arteriosclerosis, Thrombosis, and Vascular Biology. 28: 142-7. PMID 17991875 DOI: 10.1161/Atvbaha.107.151787 |
0.457 |
|
| 2007 |
Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, Hennerici M, Simunovic L, Zivin JA, Welch KM. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke; a Journal of Cerebral Circulation. 38: 3198-204. PMID 17962589 DOI: 10.1161/Strokeaha.107.493106 |
0.425 |
|
| 2007 |
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. The New England Journal of Medicine. 357: 1301-10. PMID 17898099 DOI: 10.1056/Nejmoa064278 |
0.435 |
|
| 2007 |
Hitman GA, Colhoun H, Newman C, Szarek M, Betteridge DJ, Durrington PN, Fuller J, Livingstone S, Neil HAW, Investigators C. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine. 24: 1313-1321. PMID 17894827 DOI: 10.1111/J.1464-5491.2007.02268.X |
0.324 |
|
| 2007 |
Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). The American Journal of Cardiology. 99: 632-5. PMID 17317362 DOI: 10.1016/J.Amjcard.2006.09.111 |
0.471 |
|
| 2007 |
Sillesen H, Amarenco P, Szarek M, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Simunovic L, Zivin J, Welch KMA. Po23-781 Atorvastatin Reduces Risk Of Stroke, Cardiac Events And Endarterectomy In Patients With Carotid Stenosis: A Substudy Of Sparcl Atherosclerosis Supplements. 8: 208. DOI: 10.1016/S1567-5688(07)71791-9 |
0.346 |
|
| 2007 |
Tikkanen MJ, Holme I, Szarek M, Cater NB, Kastelein JJP, Olsson AG, Lindahl C, Pedersen TR. Po23-743 Effect Of Intensive Versus Standard Statin Therapy In Younger And Older Coronary Heart Disease (Chd) Patients In The Ideal Trial Atherosclerosis Supplements. 8: 198. DOI: 10.1016/S1567-5688(07)71753-1 |
0.414 |
|
| 2007 |
Kastelein JJ, Holme I, Steeg WAvd, Barter P, Olsson AG, Cater NB, DeMicco DA, Gaffney M, Szarek M, LaRosa JC, Pedersen TR. Po23-737 A Comparison Of The Association Of On-Treatment Lipid And Apolipoprotein Parameters To Cardiovascular Events In Ideal And Tnt Atherosclerosis Supplements. 8: 196. DOI: 10.1016/S1567-5688(07)71747-6 |
0.346 |
|
| 2007 |
Holme I, Szarek M, Cater NB, Pedersen TR. Po23-736 Effect Of Adherence Differences To Atorvastatin 80 Mg (A80) Versus Simvastatin 20-40 Mg (S20-40) In Coronary Heart Disease (Chd) Patients Atherosclerosis Supplements. 8: 196. DOI: 10.1016/S1567-5688(07)71746-4 |
0.368 |
|
| 2007 |
Pedersen TR, Cater NB, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Lindahl C, Szarek M. Po23-735 Risk Reduction With Intensive Versus Standard Statin Therapy In Acute Coronary Syndrome: Ideal Trial Atherosclerosis Supplements. 8: 196. DOI: 10.1016/S1567-5688(07)71745-2 |
0.445 |
|
| 2007 |
Holme I, Szarek M, Cater NB, Pedersen TR. 204: Effect of Adherence Differences to Atorvastatin 80 mg (A80) Versus Simvastatin 20-40 mg (S20-40) in Coronary Heart Disease (CHD) Patients Journal of Clinical Lipidology. 1: 156-157. DOI: 10.1016/J.Jacl.2007.03.021 |
0.369 |
|
| 2006 |
Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC. Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? International Journal of Cancer. 119: 157-61. PMID 16450373 DOI: 10.1002/Ijc.21820 |
0.323 |
|
| 2006 |
Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. The American Journal of Cardiology. 97: 61-7. PMID 16377285 DOI: 10.1016/J.Amjcard.2005.07.108 |
0.43 |
|
| 2006 |
Olsson A, Schwarz G, Szarek M, Luo D. Th-P16:401 Atorvastatin 80 mg in acute coronary syndrome patients ≥65 years: Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study Atherosclerosis Supplements. 7: 581-582. DOI: 10.1016/S1567-5688(06)82359-7 |
0.357 |
|
| 2006 |
Holme I, Szarek M, Pedersen T. Tu-W29:7 Effect of differential treatment adherence on outcome in the ideal trial Atherosclerosis Supplements. 7: 179. DOI: 10.1016/S1567-5688(06)80696-3 |
0.306 |
|
| 2005 |
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Jama. 294: 2437-45. PMID 16287954 DOI: 10.1001/Jama.294.19.2437 |
0.438 |
|
| 2005 |
Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 28: 2508-13. PMID 16186288 DOI: 10.2337/Diacare.28.10.2508 |
0.489 |
|
| 2005 |
Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. The Journal of Investigative Dermatology. 125: 526-31. PMID 16117794 DOI: 10.1111/J.0022-202X.2005.23798.X |
0.338 |
|
| 2005 |
Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. European Heart Journal. 26: 890-6. PMID 15764620 DOI: 10.1093/Eurheartj/Ehi186 |
0.461 |
|
| 2005 |
Newman C, Tsai J, Szarek M, Luo D, Gibson E. W16-P-058 Comparative safety of atorvastatin 80MG vs I0 MG derived from analysis of 49 completed trials Atherosclerosis Supplements. 6: 115. DOI: 10.1016/S1567-5688(05)80454-4 |
0.338 |
|
| 2004 |
Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 110: 1406-12. PMID 15353498 DOI: 10.1161/01.Cir.0000141728.23033.B5 |
0.419 |
|
| 2004 |
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 110: 386-91. PMID 15262833 DOI: 10.1161/01.Cir.0000136588.62638.5E |
0.43 |
|
| 2004 |
Olsson AG, Schwartz GG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Sasiela W, Szarek M. 1117-88 High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: Results from the MIRACL trial Journal of the American College of Cardiology. 43: 3. DOI: 10.1016/S0735-1097(04)91221-1 |
0.421 |
|
| 2003 |
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 108: 1560-6. PMID 12975259 DOI: 10.1161/01.Cir.0000091404.09558.Af |
0.435 |
|
| 2003 |
Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. The American Journal of Cardiology. 92: 670-6. PMID 12972104 DOI: 10.1016/S0002-9149(03)00820-8 |
0.393 |
|
| 2003 |
Sasiela W, Szarek M, Silbershatz H, Palmer G. 1P-0296 An examination of atovarstatin safety when used in combination with amiodarone: Evidence from 44 completed clinical trials Atherosclerosis Supplements. 4: 84. DOI: 10.1016/S1567-5688(03)90365-5 |
0.307 |
|
| 2003 |
Palmer G, Silbershatz H, Szarek M, Newman C. 1P-0295 Analysis of the musculoskeletal safety of atorvastatin in a broad spectrum of patients with dyslipidemia Atherosclerosis Supplements. 4: 84. DOI: 10.1016/S1567-5688(03)90364-3 |
0.31 |
|
| 2003 |
Sasiela WJ, Szarek M, Silbershatz H, Palmer G. An examination of atorvastatin safety when used in c combination with verapamil: Evidence from 44 completed clinical trials Journal of the American College of Cardiology. 41: 336. DOI: 10.1016/S0735-1097(03)82024-7 |
0.312 |
|
| Show low-probability matches. |